Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUrGery with or without dARolutamide in high-risk and/or locally advanced prostate cancer (SUGAR)
2022-501518-67-00Phase 2Authorised
- Sponsor
- Institut Claudius Regaud
- Start
- Mar 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of darolutamide in prostate cancer (PCa) (2 arms), sponsored by Institut Claudius Regaud. Primary endpoint: Non-curable progression-free survival (NC-PFS). Planned start Mar 2023; status: authorised.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2022-501518-67-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501518-67-00.